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Lenalidomide (LND) is an anti-cancer drug and an effective derivative of thalidomide used for multiple 
myeloma therapy. Because of its poor solubility in water, LND is known to cause low oral bioavailability 
(below 33%), and as a direct consequence of this, the dosing frequency is extended thus increasing risk 
of toxicity. To improve its bioavailability and sustained release, the present study aims to formulate 
polymeric nanoparticles (NPs) for LND using [Poly (lactic-co-glycolic acid)] (PLGA) as a polymer. The 
polymeric NPs were evaluated for particle size, SEM, XRD, drug content, entrapment efficiency (EE), 
in vitro release studies and in vivo bioavailability studies in rats. The formulated NPs possessed a size of 
179±0.9 nm and a zeta potential of -24.4 ± 0.2 mV. The drug loading and EE of the optimized formulation 
was 32 ± 0.37 % and 78 ± 0.92% respectively. After oral administration of LND PLGA-NPs, the relative 
bioavailability was enhanced about 3.67-fold compared to LND. This study demonstrates the novel drug 
delivery for LND with PLGA-NPs as effective drug delivery system for sustained delivery of LND.
Uniterms: Multiple myeloma/treatment. Lenalidomide/uses. PLGA/sustained release. Polymeric 
nanoparticles/development. Solubility. 
INTRODUCTION
Classified as a plasma cell malignancy, multiple 
myeloma (MM) is identified by the bone marrow 
accumulation of terminally differentiated B cells. 
Irrespective of therapeutic progression, MM remains 
without a cure till date. (Morgenroth et al., 2011). 
Lenalidomide (LND), a thalidomide analogue is an 
immunomodulatory agent with antineoplastic and 
antiangiogenic properties which has been cleared 
for clinical application for the treatment of MM and 
transfusion dependent anemia (Kastritis, Dimopoulos, 
2007; Richardson et al., 2006). LND is off-white to pale 
yellow powder marketed with the trade name of Revlimid. 
Revlimid hemihydrate (commercial form) has poor 
oral bioavailability (< 33%) because of its inadequate 
solubility in water. LND has a shorter half-life of 3 hours 
(Song et al., 2014). Novel therapeutic approaches are, 
therefore, urgently needed. Hence, the main target of this 
study was to formulate a nanoparticulated drug delivery 
system for LND which can enhance the solubility of LND, 
consequently improving its bioavailability.
In the past few decades, nanoparticulated drug 
delivery systems have remarkably ameliorated the efficacy 
of conventional therapies, by increasing the solubility 
and decreasing the drug associated systemic toxicities 
(Maeda et al., 2000). Selective targeting and preferential 
accumulation of the drug at the tumor site can be achieved 
with nanoparticles existing within a diameter range 
of 20-200 nm, via greater permeability and retention 
(Egusquiaguirre et al., 2012). PLGA is a biodegradable and 
biocompatible polymer that is hydrolytically degraded into 
nontoxic oligomer and monomer, lactic acid, and glycolic 
acid (Vega et al., 2008). The higher surface area to volume 
ratio of PLGA NPs provides an amended pharmacokinetic 
and biodistribution profile of the therapeutic agents and 
thus reduces toxicity due to their specific aggregation at the 
target site (Noori Koopaei et al., 2014). They also improve 
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the solubility of hydrophobic compounds. Therefore, we 
expect that PLGA-NPs drug delivery system can improve 
poor oral bioavailability of LND along with sustained 
release to achieve intended therapeutic effect on level with 
the marketed products, while keeping its anti-neoplastic 
activity constant. The ultimate goal of this delivery system 
is to ensure the applicability to a wider population of 
cancer patients.
MATERIAL AND METHODS
Material
Lenalidomide (98.7%),and thalidomide (99.1%) 
(internal standard, IS) were obtained as a gift sample 
from NatcoPharmaLtd., (Hyderabad, India). PLGA, 
tetrahydrofuran, acetonitrile and acetone of HPLC grade 
was purchased from Sigma Aldrich, (Mumbai, India).
The HPLC grade water was obtained by using Milli-Q 
Academic system, Millipore (Bangalore, India). All other 
chemicals used in this study were of analytical grade.
Methods
Preparation of lenalidomide nanoparticles (Venkatesh 
et al., 2015)
The nanoprecipation technique was the method 
of choice for the preparation of the nanoparticles as 
previously described (Venkatesh et al., 2015). Briefly, 
LND (20 mg) and PLGA (100 mg) were dissolved in 
dichlromethane (5 mL; Solution A) and were subjected 
to sonication for 5 min to dissolve all substances.125 mg 
of Poloxamer F-127 was dissolved in 50 mL of deionized 
water (Solution B). Solution A was then incorporated 
into solution B under magnetic stirring at varying rpm 
using a syringe with a flow rate of 1 mL/10 min. The 
schematic representation of fabrication of LND-PLGA-
NPs is shown in Figure 1. The obtained nanosuspension 
was centrifuged, and lyophilized with cryoprotectant 
(2% sucrose) and tested for various characterization 
parameters.
Drug loading and entrapment efficiency
Drug loading and entrapment efficiency are assessed 
after freeze-drying and adding 10 mL of acetonitrile (a 
common solvent for drug and PLGA) to facilitate the 
coat of the NPs to get dissolved. The obtained suspension 
was diluted appropriately with mobile phase to determine 
drug content and entrapment efficiency. Samples were 
measured at an absorbance of 220 nm using high pressure 
liquid chromatography (Figure 2). The following equations 
were utilized for the determination of drug loading and 
entrapment efficiency of LND in NPs.
 
Characterization of nanoparticles
Particle size and zetapotential (Karri et al., 2015)
The prepared nanoparticles were washed with double 
distilled water (filtered through 0.22µm) several times 
before particle size analysis. The average particle size and 
zeta potential of the LND-PLGA-NPs were determined 
by Particle Size Analyzer (Malvern Instruments Ltd, 
UK) which allows sample measurement in the range of 
0.020-2000µm.
Scanning electron microscopy (SEM)
The uniformity of the particles (size and shape) were 
verified using SEM. Lyophilized NPs were re-suspended 
in distilled water; subsequently they were placed on a 
silicon grid and left to dry at room temperature. The 
NPs suspension was then vacuum coated with gold for 
3min before SEM analysis. Surface characteristics of the 
FIGURE 1 - Schematic representation of preparation of 
lenalidomide-PLGA-NPs.
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samples were observed under a SEM (JEOL Ltd, Japan) 
operated at 15-keV pulse under different resolutions.
Differential scanning calorimetry
DSC analysis was performed using DSC Q200. (TA 
instruments, U.S.A). The samples sealed in aluminum pans 
and heated at a rate of 10 °C per/min within a temperature 
range of 30 to 300 °C with constant nitrogen gas supply 
at a rate of 40 mL/min. DSC analysis was performed for 
PLGA, LND and LND-PLGA nanoparticles.
X-Ray diffraction (XRD) studies
An XRD peak mainly depends on the crystal size as 
they indicate the crystalline nature at particular value at 
2θ range. Molecular arrangements of LND alone and in 
nanoparticulate formulations were performed on an X-ray 
diffractometer (PANalytical X’Pert Pro, The Netherlands) 
by applying CuKα radiation. The data was collected with 
an angular range from 3° to 50°2θ in continuous mode 
using a step size of 0.0202θ and step time of 5 sec.
ANALYTICAL CONDITIONS
Quantification of LND in NPs and plasma samples 
was achieved using Shimadzu HPLC (LC 20 AD) (Kyoto, 
Japan) connected to a PDA detector (SPD-M20A). The 
chromatographic separation was performed on a Luna 
C18 column (150 × 4.6 mm) (Phenomenex, USA)with a 
mobile phase containing 20 mM KH2PO4: acetonitrile 
(86:14 v/v) at a pH of 4.2, supplied at a flow rate of 
1 mL/min. Sample detection was carried out at 220 nm. 
Data collection and instrumental control was achieved by 
means of LC Solutions software (SP 1.1). Thalidomide 
was used as internal standard (IS), as it belongs to same 
class of LND and offered acceptable resolution with 
LND peak. Retention times of LND and IS were 4.5and 
6.7 min respectively. The calibration curves were linear 
in the range of 0.5–30 µg/mL(r = 0.997) in NPs, and 
20-600 ng/mL(r=0.998) in rat plasma, suggesting that the 
method was linear over the selected range (Mannemala, 
Nagarajan, 2015b). The intra and inter-day accuracy 
and precision were within CV%≤ 6%, indicating the 
method meets the acceptance criteria (FDA, 2001). The 
extraction efficiency in case of spiked plasma samples was 
98.7±3.1%, suggesting that the procedure was consistent 
and robust (Mannemala, Nagarajan, 2015a).
In vitro release studies (Gomathi et al., 2014)
The dialysis bag diffusion technique was incorporated 
to analyze the in vitro drug release of LND from NPs. The 
drug loaded NPs were placed in the dialysis bag (3 mL) and 
immersed into 250 mL of HCl buffer (pH 1.2) for a period 
of 48 h. The receptor phase was stirred and the temperature 
was maintained at 37 °C. At predetermined intervals (0, 
0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 and 48 h), samples were 
drawn from the receptor compartment and equal volumes of 
fresh media were replaced to maintain sink equilibrium. The 
amount of drug dissolved was quantitated by high pressure 
liquid chromatography at 220 nm.
Cytotoxicity studies
Human multiple myeloma U266 cells were obtained 
from National center for cellular sciences (NCCS), 
Pune, India. Minimal essential medium (MEM) was 
used to culture the cells which was further supplemented 
with 10% fetal bovine serum (FBS), 3% L-glutamine, 
FIGURE 2 -Representative chromatograms corresponding to 
(a) lenalidomide loaded PLGA-NPs with IS (thalidomide) and 
blank PLGA-NPs and (b) lenalidomide spiked in rat plasma with 
IS (thalidomide) and processed blank rat plasma.
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100 U/mL pencillin-G and 100 µg/mL streptomycin 
(Himedia) in a humidified atmosphere of 5% CO2:95% 
air at 37±2oC. A 96 well microtiter plate was seeded with 
1lakh cells per milliliter of the U266 cell suspension for 
performing the cytotoxicity assay. After 24 h of seeding, 
fresh medium containing different concentrations of 
LND-PLGA-NPs suspension was added to the plate. A 
10 mg/mL working concentration was freshly obtained by 
dissolving 0.5 mg of nanoparticles in 4.5 mL of DMSO 
and was filtered through a 0.22 µ filter prior to each assay. 
Blank cells (cells without test samples) were incubated 
with DMSO whose negligible presence in the wells was 
not found to be affecting the interfering with experiments.
In vivo bioavailability studies (Ma et al., 2012)
All the animal investigations were performed as 
per the requisite protocol approved by the Institutional 
Animal Ethical Committee of JSS College of Pharmacy, 
Ooty, India. Approval letter no (JSSCP/IAEC/M.PHARM/
PH.ANALYSIS/02/2012-13). In vivo studies were carried 
out in healthymale Wistar rats of 150–200g.The animals 
were housed in individual cages in the animal house for 
10 days prior to the initiation of the study to facilitate 
environmental acclimatization and had access to feed and 
water ad libitum.12 h circadian rhythms were maintained 
and the temperature was kept constant throughout the 
study period. The animals were divided into 3 groups 
containing three animals in each group. The animal dose 
(30 mg/kg) was chosen based on the surface area ratio 
from human to rat. Group 1 pertained to the control, 
group 2 were treated with free drug and group 3 were 
treated with LNDPLGA-NPs.Blood samples, each not 
more than 500 µL were withdrawn from the tail vein at 
0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 and 48 h period using a 
sterilized syringe. Fasting blood samples (0th hour) were 
withdrawn early in the morning. The blood samples were 
collected in ria-vials containing anticoagulant (100 µL of 
11% sodium citrate) and centrifuged at 4000 rpm for 15 
min to separate the plasma and was stored at -20oC. The 
plasma samples were deproteinized by mixing the samples 
with equal volumes of 10% perchloric acid and vortexed 
for 2 min followed by centrifugation at 4000 rpm for 15 
min. The supernatant liquid was separated and analyzed. 
The amount of LND in plasma samples by was estimated 
using HPLC at optimized chromatographic conditions.
Statistical analysis
Statistical data were analyzed using GraphPad 
Prism® 6 program (Graph pad Inc., USA).
In vitro
The experiments were replicated at least three times. 
The amount of each drug in the receptor compartment was 
estimated through HPLC. Data were shown as mean±S.D 
(n = 3). The differences between two samples were 
determined by student’s t-test (p < 0.05).
In vivo
The experiments were replicated at least six times. 
The amount of drug in plasma was estimated through 
HPLC. Data was analyzed by one-way analysis of variance 
(ANOVA), and the mean differences between groups were 
considered to be significant at p<0.05. Data were shown 
as mean±S.D (n = 6). The relative oral bioavailability of 
NFV was calculated according to the equation:
 
AUCA and AUCB represent the area under the 
blood concentration time curve of LND-PLGA-NPs and 
LND suspension, and doseA and doseB mean the dose of 
LND-PLGA-NPs and LND suspension following oral 
administration.
RESULTS AND DISCUSSION
Preparation
The nanoparticles containing LND were successfully 
obtained by the nanoprecipitation method. Different 
batches of LND-PLGA-NPs were prepared using different 
concentrations (100-500 mg) of polymer by keeping drug 
concentration constant with varying stirring rates (500-
1500 rpm). During the procedure, polymer concentration 
increment caused a dramatic increase in size of the NPs 
(142-265 nm) and entrapment efficiency (16-78%). But 
after reaching a concentration of 300 mg, the saturation 
rate and entrapment of the drug to that of polymer were 
decreased. In the other hand, the stirring rate showed a 
significant influence on the size of NPs, i.e., at higher 
stirring rate (1500 rpm) the NPs particle size was reduced, 
whereas at lower stirring rate the particle size of NPs was 
not reduced, effectively. Drug loading has a very important 
influence in the polymeric NPs preference over others 
such as solid lipid NPs. The improper entrapment leads 
to the initial burst of the NPs, which hinders its sustained 
release property (Venkatesh et al., 2015). Hence, the batch 
with highest entrapment efficiency (78±0.92%) and drug 
loading (32±0.37%) was chosen as formulation of choice 
for further characterization.
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Particle size and zeta potential analysis
The mean particle size of LND NPs was found to 
be179.4±0.9nm (Figure 3a) and the zeta potential were 
found to be -24.4±0.2mV (Figure 3b). The experiment 
was performed in triplicate (n=3) in order to ensure 
reproducibility and minimize the error. PDI values were 
found to be 0.464, which indicates that the system has a 
relatively narrow distribution. This narrow distribution 
ensures good stability of PLGA-NPs suspension by 
avoiding problems such as Ostwald ripening. Zeta 
potential reports had showed that the prepared PLGA 
nanoparticles had typical negative zeta potential attributed 
to PLGA preparations due to carboxyl groups present in 
their structure. The Zeta potential of the prepared NPs 
is also a prominent factor to ensure stability. Highly 
charged NPs are capable to remain stable as colloidal 
suspension. Since the prepared NPs have shown high zeta 
potential which ensure the stability of the formulation. The 
morphological evaluation (size, shape and morphology) of 
the LND-PLGA-NPs was performed using SEM (Figure 
4). SEM studies confirm that nanoparticles are in the range 
of 50-300 nm with smooth surface and spherical shape 
which ensures the drug release in sustained manner.
FIGURE 3 - (a) Particle Size; (b) Zeta potential of lenalidomide-PLGA-NPs.
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DSC and XRD studies
The DSC thermograms of LND, PLGA, and NPs 
are shown in Figure 5. The DSC curve of LND exhibit 
an exothermic peak at peak temperature of 265 oC 
corresponding to its melting point. The polymer, PLGA 
had shown peak at a temperature of 65.12. As per the DSC 
graph of LND-PLGA-NPs, the characteristic exothermic 
peak of LND was observed with minimal intensity and 
shifted to lower temperature range. This indicates the 
conversion of crystalline nature of LND to amorphous 
form which ensures the better stability. Furthermore, it 
also confirms that LND was entrapped into PLGA-NPs. 
Reported findings have suggested that with an increase 
in the amorphous nature of the therapeutic system, a 
corresponding increase in the efficiency of delivery is 
observed (Abdelwahed et al., 2006).
The physical nature of pure LND, PLGA-NPs and 
LND loaded PLGA-NPs were observed using X-ray 
diffraction analysis (Figure 6). Pure LND possessed a 
crystal structure when compared to LND-PLGA-NPs, 
which were in amorphous form. Pure LND has shown 
multiple peaks at different 2θ values indicating crystalline 
form of pure LND. However, the intensity of LND 
peaks were greatly reduced in PLGA-NPs signifying the 
conversion of crystalline form LND to amorphous form 
and LND loading in to PLGA-NPs.
In vitro drug release
In vitro release studies of LND loaded PLGA-NPs 
were studied up to 48 h in HCl buffer (pH 1.2) for a period 
of 48 h. The summarized in vitro release of LND-PLGA-
NPs is shown in Figure 7, as cumulative percentage drug 
release. The NPs has shown a biphasic pattern of drug 
release. Initially, a burst release of drug was observed 
(39%) followed by sustained release. 40% of LND was 
released within 6 hours and about 76.89 ± 2.99% and 83 
± 3.90% was released in 24 and 48 h respectively. This 
clearly depicts the pronounced time prolongation of the 
drug release. The initial burst release of drug may be due 
to drug desorption of surface entrapped or adhered LND 
from the particle surface, and the sustained release can be 
characterized by the drug diffusion through the polymeric 
matrix and subsequent dissolution of drug or erosion of 
the polymeric matrix. In dissolution media, the release of 
LND from PLGA-NPs occurred either by the formation of 
holes in the particles or by their disintegration. A constant 
rate of release of the drug from the NPs will facilitate better 
drug control in vivo.
FIGURE 4 - SEM photograph of lenalidomide -PLGA-NPs.
FIGURE 5 -DSC curves of lenalidomide, PLGA, and 
lenalidomide -PLGA-NPs.
FIGURE 6 -XRD of lenalidomide, PLGA and lenalidomide-
PLGA-NPs.
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Cytotoxicity studies
The extent of cell viability due to LND-PLGA-
NPs was examined by MTT assay in U266 cells. Eight 
concentrations (1-100 µg/mL) of LND-PLGA-NPs were 
prepared and tested yielding proof that the NPs exhibited 
significant toxicity against U266 cells. Cytotoxicity 
concentration (CTC50) value for NPs was calculated from 
the concentration and subsequent response; it was found 
to be34.09 µg/mL (Figure 8). This proves the cytotoxic 
potential of the PLGA-NPs and lends further credence to 
the viability if this concept.
In vivo bioavailability studies
The formulations (LND aqueous suspension, 
dispersion of the LND-loaded PLGA NPs) were 
administered by oral gavage with a single dose of 30 
mg/kg. The nanoparticles were dispersed in ultra-pure 
water. Table I and Figure 9 shows the pharmacokinetic 
data of the drug suspension and nanoparticles. Figure 
9 depicts a remarkable difference in bioavailability 
between LND PLGA NPs and LND suspension. After 
oral administration of LND suspension, the drug 
was rapidly absorbed and a Cmax of 0.57±0.003 µg/
mL was reached in 1.5 h. Consequently, the plasma 
concentration decreased abruptly, as the drug was 
rapidly distributed and metabolized and was detected 
up to 48 h after administration, resulting in low AUC0-t 
(4.9695 ± 0.036 h.µg/mL) and low t½ (9.762±1.9 h). 
Figure 9 shows that peak plasma concentration for LND 
PLGA NPs (Cmax) of approximately1.37±0.007 µg/mL 
was achieved at 4 h.
Table I depicts the pharmacokinetic parameters 
Cmax, AUC0-t, t½and tmax after oral administration of LND 
loaded PLGA-NPs and suspension. From Table I, it 
can be perceived that, the Cmax value for LND PLGA 
NPs (1.377±0.007) was significantly higher than LND 
suspension (0.57±0.003). In the same way, the t½ was rapid 
for LND-PLGA-NPs (20.2183±2.2), when compared to 
LND suspension (9.762 ±1.9). From the data in Table I, 
it is apparent that, the tmax was also rapid for LND PLGA 
NPs (4.0±0.026), when compared to LND suspension 
(1.5±0.024). This may be due to the primarily related 
prolonged absorption phase and sustained release of 
PLGA-NPs. Likewise, the area under curve AUC for LND 
PLGA NPs was 3-fold higher than the LND suspension. 
Finally, the relative bioavailability for LND PLGA NPs 
was computed and found to be 367.80%, suggesting 
better absorption of LND-PLGA-NPs compared to 
the suspension. On the contrary, particles belonging to 
nanoscale are easily absorbed into the intestinal folds, 
while larger particle surface area to volume offers faster 
FIGURE 8 - MTT assay of lenalidomide - PLGA-NPs.
FIGURE 7 -Release rates of lenalidomide from PLGA-NPs in 
vitro in HCl buffer pH 1.2 (mean±SD, n = 3).
FIGURE 9 - Mean plasma concentration time profiles of 
lenalidomide in wistar rats: (a) lenalidomide suspension (b) 
lenalidomide PLGA-NPs with (mean±SD, n=6).
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TABLE I - Pharmacokinetic parameters of lenalidomide after oral administration of LND loaded PLGA-NPs and suspension at the 
dose of 30 mg/kg
Parameters LND Suspension LND-PLGA-NPs
Cmax(µg/mL) 0.57±0.003 1.377±0.007
AUC0-t(h.µg/mL) 4.9695±0.036 18.276±0.042
t½(h) 9.762±1.9 20.2183±2.2
tmax(h) 1.5±0.024 4.0±0.026
Frel(%) - 367.80
drug dissolution. In current study, there was a significant 
improvement in bioavailability with LND-PLGA-NPs 
in contrast to LND suspension. The reasons may be 
many, but it is assumed that nano based drug delivery 
system enhances the bioavailability by modulating the 
physiochemical properties of poorly soluble drugs. 
Overall, our results suggest that LND-PLGA-NPs are most 
likely to have great potential as a therapeutic, by enhanced 
pharmacokinetic profiles.
CONCLUSION
Nanoparticles of a poorly soluble drug LND 
were successfully formulated by nano-precipitation 
method using PLGA as polymer. The particle size, 
zeta and SEM reports confirmed that the size of LND-
PLGA-NPs was below 200 nm with spherical shape and 
uniform size distribution. DSC and XRD analysis of 
NPs confirmed the conversion of the crystalline nature 
of LND to amorphous form and drug entrapment within 
the NPs. Cytotoxic studies suggested that LND-PLGA-
NPs were toxic towards U266 cancer cells. In vitro 
and in vivo studies confirmed that LND-PLGA-NPs 
demonstrate increased bioavailability with a sustained 
release up to 48 h. Due to their hydrophobic nature, 
conventional chemotherapeutics of LND suffer from 
poor solubility and an inability to penetrate the tumors 
(poor bioavailability). This results in grave side effects 
that include immune system depletion and metastasis 
to neighboring organs. Hence, the present PLGA 
nanoparticles can effectively solve the solubility problem 
and enhance the bioavailability of LND.
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